Related Experiment Video
Updated: Apr 28, 2026

Three-Dimensional 3D Tumor Spheroid Invasion Assay
Published on: May 1, 2015
Integrin β3 links therapy resistance and cancer stem cell properties
Abstract:
Heterogeneity in tumour cell properties underlies many treatment failures. Understanding the sources of such heterogeneity has proved to be challenging, but remains critical to improving patient outcomes. Integrin α(v)β₃ expression in multiple types of solid tumour stem cells is now shown to control a pro-survival pathway that contributes to therapy resistance.
Insights
Tumor cell heterogeneity causes treatment failure. Integrin α(v)β₃ in solid tumor stem cells activates a survival pathway, contributing to therapy resistance and impacting patient outcomes.
Area of Science:
- Oncology
- Cell Biology
- Molecular Medicine
Background:
- Tumor cell heterogeneity is a significant challenge in cancer treatment, leading to therapy failure.
- Identifying the sources of this heterogeneity is crucial for developing more effective therapeutic strategies.
Related Concept Videos
Intracellular Signaling Affects Focal Adhesions
Some...
Activation of Integrins
In "outside-in signaling," external factors in the extracellular space bind to exposed ligand binding sites on integrins. This causes the inactive protein to undergo a conformational change to become active. Integrins are often clustered on the cell membrane. Repetitive and regularly spaced ligand binding...
Integrins
Some ECM proteins assemble into a basement membrane to which the remaining components adhere. Proteoglycans typically form the bulk of the ECM while fibrous proteins, like collagen,...
Cancer Stem Cells and Tumor Maintenance
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer Stem Cells and Tumor Maintenance
Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal

